NICE wants more data on Simponi for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, wants more information on the clinical- and cost-effectiveness of Merck & Co/J&J's rheumatoid arthritis (RA) drug Simponi (golimumab) before it can decide whether to recommend its use in the NHS.